Prestige BioPharma inks two new deals for its biosimilar trastuzumab
Category: #health  By Mateen Dalal  Date: 2019-07-10
  • share
  • Twitter
  • Facebook
  • LinkedIn

Prestige BioPharma inks two new deals for its biosimilar trastuzumab
  • The company would be able to supply and commercialize its biosimilar across Russia under the latest of the two deals.
     
  • The second deal, meanwhile, gives Prestige access to certain parts of Europe.

Prestige BioPharma (Prestige), a renowned Singapore-based biopharmaceutical company, has reportedly announced that it has signed two new agreements that would allow it to supply and commercialize its biosimilar trastuzumab, HD201, across Russia and parts of Europe.

Reports cite, the company signed the latest of the two deals with Pharmapark LLC, a private Russian pharmaceutical firm that is marketing five biosimilars across Russia at present. Meanwhile, the company inked the second deal with Mundipharma, a UK-based pharmaceutical company.

According to reports, the Mundipharma agreement would give the trastuzumab biosimilar access across a number of European countries including Spain, France, Sweden, Norway, Finland, Denmark, Austria, Switzerland and Portugal following the drug’s approval by the European Commission.

The CEO of Prestige BioPharma, Lisa S. Park, PhD, stated that the company is thrilled to collaborate with Mundipharma to commercialize its leading biosimilar across select European markets. Park further added that the proposed partnership is a crucial milestone for Prestige as it will boost the global availability of trastuzumab and benefit more patients through its accessibility and quality.

The new deals reportedly come as the latest in a string of agreements concerning the biosimilar for the Singapore-based biopharma company; in the fourth quarter of 2018, Prestige inked a licensing agreement with Cipla Limited to supply and commercialize trastuzumab across emerging markets. Earlier, the company also announced a deal with Alvogen to distribute the biosimilar across Eastern and Central Europe.

Sources familiar with the matter claim that the proposed biosimilar is currently being reviewed by the European Medicines Agency. Moreover, the company also plans to submit an application for the biosimilar with the U.S. FDA by the end of 2019.

Source Credits:

https://www.centerforbiosimilars.com/news/prestige-biopharma-strikes-2-more-deals-for-biosimilar-trastuzumab-hd201

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

TPG Rise Climate Fund raises $5.4Bn to support new climate solutions
TPG Rise Climate Fund raises $5.4Bn to support new climate solutions
By Mateen Dalal

TPG Rise Climate Fund, the climate investing fund of TPG’s global impact investing platform TPG Rise, has recently raised its first close of $5.4 billion, bringing together an exclusive blend of funding from some of the top institutional invest...

Baby nutrition firm ByHeart nabs $90Mn in Series B funding round
Baby nutrition firm ByHeart nabs $90Mn in Series B funding round
By Mateen Dalal

ByHeart, a fully integrated infant nutrition company, has reportedly secured $90 million in Series B funding which the company plans to use for the launch of its baby formula and support the development of its pipeline of nutrition items for chi...

UAE extends travel ban for Indians amid strict COVID-19 guidelines
UAE extends travel ban for Indians amid strict COVID-19 guidelines
By Mateen Dalal

United Arab Emirates (UAE) has reportedly extended travel ban for individuals travelling from India and several other south Asian countries on the pretext of COVID-19 guidelines. As reported by Etihad Airlines, the ban will be followed till 31st July...